The primary objective of this pilot study is the assessment of the safety of the ISS500 System in patients who have experienced an acute ischemic stroke within the anterior circulation. The secondary objectives of this study are to examine the effectiveness of the ISS500 System implantation in the treatment of acute ischemic stroke.
The study is an open label study in which a comparative group of patients will be prospectively selected from a resource of clinical trial data, the Virtual International Stroke Trials Archive (VISTA), on the basis of similar eligibility criteria and match for principal prognostic variables available at trial entry. Data from patients will be transferred to VISTA in a real time or at most, weekly basis and comparative group patients will be prospectively matched throughout the recruitment period. The VISTA investigators will be blinded to treatment group when receiving data from BrainsGate. The VISTA investigators will match each recruited BrainsGate patient with 3 patients from the VISTA archive. The matching criteria will include age ± 4 years; baseline NIH score matched exactly, and side of infarct. In addition, to the end of treatment visit, in which implanted patients will undergo a device removal procedure, two follow-up visits will be performed. The visits should be performed at 30±5, and at 90±5 post enrollment. Aggregate trial duration will be \~100 days per patient, and the overall study duration will be up to 18 months.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
98
ISS SPG stimulation and standard of care
Postgraduate Institute of Medical Education and Research
Chandigarh, India
Nizam's Institute of Medical Research Punjagutta, Hyderabad.
Hyderabad, India
Treatment successful completion
The need to stop the treatment sessions completely or alternately.
Time frame: 5 Days
Adverse Events profile at 90 Day compared to VISTA trials data
Adverse Events profile at 90 days post implantation will be compared to the data retrieved form the VISTA trials.
Time frame: 90 Days
The distribution of modified Rankin scale scores at 90 days
Shift in the distribution of modified Rankin Scale (mRS) scores at 90 days Favorable outcome is mRS score between 0 and 2
Time frame: 90 Days
NIHSS scores at 90 days
The distribution of total NIHSS scores at 90 days - binary NIHSS (defined as the proportion of favorable outcomes assessed using the NIHSS scale, where as favorable outcome was a complete recovery (NIHSS 0 or 1) or an improvement by 9 or more points in the NIHSS score
Time frame: 90 Days
Proportion of patients achieving a Barthel index at 90 days
The proportion of patients achieving a Barthel index of 95-100 (versus 0-90) at 90 days
Time frame: 90 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.